Repligen Corp

Repligen Corp

Repligen Corporation is a specialised life‑sciences company that supplies consumables, materials and systems used in the manufacturing of biologic medicines such as monoclonal antibodies. Its product mix includes chromatography resins (notably Protein A), filtration systems and process‑intensification technologies that often generate recurring revenue from repeat purchases. The business benefits from long development cycles and close relationships with large biopharma customers, offering potentially resilient margins, but growth is tied to demand for biologics and capital spending in biomanufacturing. At a market capitalisation of about $8.8bn, Repligen can be seen as a mid/large‑cap service provider to the booming biologics industry. Key considerations for investors include product concentration, supply‑chain execution, competition and the potential for acquisitions to add scale. This is general educational information, not personal advice — values can fall as well as rise and suitability depends on your circumstances.

Stock Performance Snapshot

Buy

Analyst Rating

Analysts recommend buying Repligen Corp's stock with a target price of $198.4, indicating strong growth potential.

Above Average

Financial Health

Repligen Corp shows strong revenue and cash flow, indicating good financial performance and stability.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Baskets Featuring RGEN

The Plasma Profit Pipeline

The Plasma Profit Pipeline

Biopharmaceutical leader CSL reported a 14% surge in annual profit, fueled by its plasma division's success. This highlights a growing investment opportunity in companies involved in the plasma-derived therapies market and the broader bioprocessing supply chain.

Published: August 19, 2025

Explore Basket
Pharma's American Reshoring Wave

Pharma's American Reshoring Wave

AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.

Published: July 23, 2025

Explore Basket

Why You’ll Want to Watch This Stock

📈

Recurring revenue model

Consumables such as resins and filters often lead to repeat sales, supporting stable revenue streams; however, past performance is not a guarantee of future results.

Process innovation focus

Solutions that increase manufacturing efficiency can drive adoption and higher margins, though technology cycles and competition may affect uptake.

🌍

Biologics market exposure

Demand for monoclonal antibodies and biosimilars supports long‑term growth potential, but revenue can be sensitive to industry spending and regulation.

Why invest with Nemo?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

ABT

Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.

A

Agilent Technologies Inc.

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. It offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.

ALGN

Align Technology Inc.

Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.

Frequently asked questions